Amit Kumar Acquires 21,000 Shares of Anixa Biosciences (NASDAQ:ANIX) Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar bought 21,000 shares of the stock in a transaction on Friday, June 12th. The shares were bought at an average price of $2.50 per share, with a total value of $52,500.00. Following the acquisition, the chief executive officer owned 630,812 shares of the company’s stock, valued at $1,577,030. This trade represents a 3.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Anixa Biosciences Trading Up 3.1%

Shares of ANIX opened at $2.69 on Thursday. Anixa Biosciences Inc has a 12 month low of $2.32 and a 12 month high of $5.46. The stock has a fifty day moving average price of $2.78 and a 200-day moving average price of $3.05. The firm has a market cap of $91.51 million, a PE ratio of -8.68 and a beta of 0.59.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03. As a group, research analysts forecast that Anixa Biosciences Inc will post -0.31 EPS for the current year.

Analyst Ratings Changes

ANIX has been the subject of a number of recent research reports. D. Boral Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a research note on Wednesday, April 8th. HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Citigroup reiterated a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Finally, Wall Street Zen cut shares of Anixa Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $8.50.

Institutional Investors Weigh In On Anixa Biosciences

Large investors have recently made changes to their positions in the stock. NewEdge Advisors LLC purchased a new stake in shares of Anixa Biosciences in the second quarter valued at about $33,000. Cetera Investment Advisers purchased a new position in Anixa Biosciences in the fourth quarter worth approximately $35,000. Northwestern Mutual Wealth Management Co. grew its position in Anixa Biosciences by 2,000.0% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after acquiring an additional 10,000 shares during the period. Benjamin Edwards Inc. purchased a new position in Anixa Biosciences in the second quarter worth approximately $37,000. Finally, Millennium Management LLC purchased a new position in Anixa Biosciences in the fourth quarter worth approximately $38,000. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.